Skip to main content

Table 1 Baseline characteristics of TECOS participants who did not have a within-trial nonfatal myocardial infarction (MI), and for those participants with a nonfatal MI, split by sitagliptin or placebo treatment

From: Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

Characteristic

Patients without a nonfatal MI during the trial randomized to sitagliptin or placebo

N = 14,055

Patients with a nonfatal MI during the trial

P-value*

Sitagliptin

N = 289

Placebo

N = 302

Age at randomization (years)a

65.0 (60.0, 71.0)

67.0 (62.0, 74.0)

66.0 (60.0, 72.0)

0.1414

Female

4161 (29.6%)

56 (19.4%)

75 (24.8%)

0.1103

Hispanic or Latino

1754 (12.5%)

17 (5.9%)

22 (7.3%)

0.4924

Race

0.4603

 White

9472 (67.4%)

235 (81.3%)

234 (77.5%)

 

 Black

422 (3.0%)

10 (3.5%)

14 (4.6%)

 

 Asian

3184 (22.7%)

38 (13.1%)

42 (13.9%)

 

 Other

977 (7.0%)

6 (2.1%)

12 (4.0%)

 

Region

0.5023

 Latin America

1445 (10.3%)

10 (3.5%)

11 (3.6%)

 

 Asia Pacific and other

4377 (31.1%)

98 (33.9%)

84 (27.8%)

 

 Western Europe

1977 (14.1%)

48 (16.6%)

50 (16.6%)

 

 Eastern Europe

3822 (27.2%)

63 (21.8%)

68 (22.5%)

 

 North America

2434 (17.3%)

70 (24.2%)

89 (29.5%)

 

Durationb of type 2 diabetes (years)

10.0 (5.0, 16.0)

11.0 (6.0, 18.0)

11.0 (6.0, 16.0)

0.3233

Diabetes therapy at baseline (alone or in combination)

 Sulfonylurea

6394 (45.5%)

110 (38.1%)

125 (41.4%)

0.4085

 Metformin

11,501 (81.8%)

212 (73.4%)

235 (77.8%)

0.2069

 Thiazolidinedione

376 (2.7%)

9 (3.1%)

9 (3.0%)

0.9245

 Insulin

3208 (22.8%)

98 (33.9%)

98 (32.5%)

0.7063

Preexisting vascular disease

13,975 (99.4%)

288 (99.7%)

302 (100.0%)

0.4890

Coronary artery disease

10,312 (73.4%)

261 (90.3%)

269 (89.1%)

0.6208

Cerebrovascular disease

3445 (24.5%)

72 (24.9%)

65 (21.5%)

0.3289

Peripheral arterial disease

2348 (16.7%)

40 (13.8%)

42 (13.9%)

0.9814

Prior MI

5899 (42.0%)

171 (59.2%)

170 (56.3%)

0.4790

Prior congestive heart failure

2511 (17.9%)

62 (21.5%)

61 (20.2%)

0.7072

Previous atrial fibrillation/flutter

1086 (7.7%)

32 (11.1%)

45 (14.9%)

0.1670

NYHA classification

0.3241

 1

510 (20.3%)

16 (25.8%)

8 (13.1%)

 

 2

1256 (50.0%)

24 (38.7%)

30 (49.2%)

 

 3

339 (13.5%)

6 (9.7%)

10 (16.4%)

 

 4

11 (0.4%)

1 (1.6%)

1 (1.6%)

 

 Not available

395 (15.7%)

15 (24.2%)

12 (19.7%)

 

Qualifying HbA1c (mmol/mol)

55.2 (50.8, 60.7)

56.1 (51.0, 61.7)

55.2 (51.9, 59.6)

0.3239

Qualifying HbA1c (%)

7.2 (6.8, 7.7)

7.3 (6.8, 7.8)

7.2 (6.9, 7.6)

0.3239

eGFR (mL/min/1.73 m2)

73.0 (60.0, 88.0)

68.5 (55.0, 84.0)

69.0 (56.0, 88.0)

0.2918

Urine albumin creatinine ratio (g/mol creatinine)

10.6 (3.5, 35.0)

12.2 (5.3, 52.7)

13.8 (5.3, 43.9)

0.9026

Heart rate (bpm)

72.0 (65.0, 79.0)

70.0 (62.0, 78.0)

71.0 (62.0, 80.0)

0.0595

Body mass index (kg/m2)

29.5 (26.3, 33.2)

29.8 (26.6, 33.5)

30.4 (27.2, 34.3)

0.1480

Weight (kg)

83.0 (71.0, 96.0)

85.0 (75.0, 98.0)

88.5 (75.0, 100.0)

0.1517

Height (cm)

168.0 (160.0, 174.2)

169.4 (163.2, 175.3)

170.0 (162.6, 176.0)

0.5036

Cigarette smoking status

0.9049

 Current

1589 (11.3%)

44 (15.2%)

43 (14.2%)

 

 Former

5575 (39.7%)

129 (44.6%)

133 (44.0%)

 

 Never

6891 (49.0%)

116 (40.1%)

126 (41.7%)

 

Systolic blood pressure (mmHg)

133.0 (124.0, 145.0)

136.0 (124.0, 146.0)

135.0 (124.0, 148.0)

0.9803

Diastolic blood pressure (mmHg)

79.0 (70.0, 84.0)

77.0 (68.0, 82.0)

76.0 (68.0, 85.0)

0.3050

LDL-C

84.0 (65.0, 109.0)

81.0 (63.0, 99.6)

82.1 (65.6, 108.1)

0.4128

Medications taken at time of randomization

 Statins

11,213 (79.8%)

238 (82.4%)

248 (82.1%)

0.9408

 ACE inhibitors or angiotensin receptor blockers

11,040 (78.5%)

238 (82.4%)

255 (84.4%)

0.4959

 Diuretics

5727 (40.7%)

127 (43.9%)

150 (49.7%)

0.1633

 Calcium channel blockers

4730 (33.7%)

104 (36.0%)

118 (39.1%)

0.4386

 Beta blockers

8876 (63.2%)

210 (72.7%)

221 (73.2%)

0.8881

 Aspirin

11,027 (78.5%)

244 (84.4%)

235 (77.8%)

0.0403

  1. Data shown are median (interquartile range) or N (%)
  2. ACE angiotensin-converting enzyme, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, LDL-C low-density lipoprotein cholesterol, NYHA New York Heart Association, TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin
  3. *P-value is for placebo vs sitagliptin in patients with a nonfatal MI
  4. aAge is missing among patients enrolled in Lithuania because the entire birth date including year was not available
  5. bDuration = (year of randomization − year of diagnosis) + 1
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840